Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Tetsuya Taura

Showing results (1-10 of 5) with videos related to

Pageof 1
Sort By:
Cephalalgia : an International Journal of Headache|February 25, 2021
Migraine therapeutics differentially modulate the CGRP pathwayMinoti Bhakta, Trang Vuong, Tetsuya Taura, et al.
Proceedings of the National Academy of Sciences of the United States of America|April 16, 2025
Development of DPP-4-resistant CXCL9-Fc and CXCL10-Fc chemokines for effective cancer immunotherapyJennie Lugassy, Noor Abdala-Saleh, Ghada Jarrous, et al.
Frontiers in Immunology|October 30, 2024
PD-1 and CTLA-4 serve as major gatekeepers for effector and cytotoxic T-cell potentiation by limiting a CXCL9/10-CXCR3-IFNγ positive feedback loopNoor Abdala-Saleh, Jennie Lugassy, Akshatha Shivakumar-Kalvhati, et al.
Mabs|June 29, 2023
Modifying antibody-FcRn interactions to increase the transport of antibodies through the blood-brain barrierJason Tien, Dmitri Leonoudakis, Ralitsa Petrova, et al.
Plos One|September 10, 2016
Targeting Attenuated Interferon-α to Myeloma Cells with a CD38 Antibody Induces Potent Tumor Regression with Reduced Off-Target ActivitySarah L Pogue, Tetsuya Taura, Mingying Bi, et al.
Pageof 1

Showing results (1-10 of 5) with videos related to

Sort By:
Pageof 1
Cephalalgia : an International Journal of Headache|February 25, 2021
Migraine therapeutics differentially modulate the CGRP pathwayMinoti Bhakta, Trang Vuong, Tetsuya Taura, et al.
Proceedings of the National Academy of Sciences of the United States of America|April 16, 2025
Development of DPP-4-resistant CXCL9-Fc and CXCL10-Fc chemokines for effective cancer immunotherapyJennie Lugassy, Noor Abdala-Saleh, Ghada Jarrous, et al.
Frontiers in Immunology|October 30, 2024
PD-1 and CTLA-4 serve as major gatekeepers for effector and cytotoxic T-cell potentiation by limiting a CXCL9/10-CXCR3-IFNγ positive feedback loopNoor Abdala-Saleh, Jennie Lugassy, Akshatha Shivakumar-Kalvhati, et al.
Mabs|June 29, 2023
Modifying antibody-FcRn interactions to increase the transport of antibodies through the blood-brain barrierJason Tien, Dmitri Leonoudakis, Ralitsa Petrova, et al.
Plos One|September 10, 2016
Targeting Attenuated Interferon-α to Myeloma Cells with a CD38 Antibody Induces Potent Tumor Regression with Reduced Off-Target ActivitySarah L Pogue, Tetsuya Taura, Mingying Bi, et al.
Pageof 1